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Induced pluripotent stem cells (iPSCs) hold much promise in the quest for personalised cell therapies.
However, the persistence of founder cell mitochondrial DNA (mtDNA) mutations limits the potential of
iPSCs in the development of treatments for mtDNA disease. This problem may be overcome by using
oocytes containing healthy mtDNA, to induce somatic cell nuclear reprogramming. However, the extent to
which somatic cell mtDNA persists following fusion with human oocytes is unknown. Here we show that
human nuclear transfer (NT) embryos contain very low levels of somatic cell mtDNA. In light of a recent
report that embryonic stem cells can be derived from human NT embryos, our results highlight the
therapeutic potential of NT for mtDNA disease, and underscore the importance of using human oocytes to
pursue this goal.
T
he possibility of generating patient-specific embryonic stem (ES) cells emerged from the seminal discoveries
that the oocyte cytoplasm has the capacity to reprogram differentiated cells to an early embryonic state1, and
that pluripotency can be harnessed by deriving embryonic stem (ES) cells from the inner cell mass (ICM) of
the pre-implantation blastocyst2. Isogenic ES cells have the potential to increase the efficacy of cellular therapies in
treating degenerative disease by reducing the risk of immune rejection3.
Fusion of differentiated cells with enucleated oocytes, otherwise known as nuclear transfer (NT), has been
reported in a variety of species with variable success rates4. Until recently, there had been only a few isolated
reports of blastocyst formation followingNT in human oocytes5–7 and the only success in generating ES cells from
humanNT embryos involved leaving the oocyte’s nuclearmaterial intact, resulting in the formation of triploid ES
cells8. However, it has recently been reported that this limitation can be overcome by using caffeine to prevent
premature activation of oocytes during the NT procedure9.
The discovery that ectopic expression of SOX2, OCT4, KLF4 andMyc can induce differentiated cells to revert to
an ES cell-like state, resulting in the production of induced pluripotent stem cells (iPSCs)10, raised the possibility
of generating patient-specific cell therapies without the need for oocytes. This is an area of intensive research,
which holds much promise for the future of isogenic therapies in regenerative medicine. However, the broad
spectrum of degenerative diseases associated withmutations inmitochondrial DNA (mtDNA)11 are unlikely to be
amenable to iPSC-based therapies due to the persistence of the somatic cell mtDNA mutations.
Mitochondrial DNA mutations cause defects in respiratory chain function resulting in multi-system disease
affecting at least 1 in 10,000 adults12. However, pathogenic mutations are more prevalent and are estimated to be
present in 1 in 200 babies born13. Pathogenicity is largely determined by the ratio of mutated to non-mutated
mtDNA molecules, with a typical minimum critical proportion of 60–90% mtDNA mutation before phenotypic
effects are observed11. At present, there are no curative treatments for mtDNA disease and interventions are
largely limited to managing symptoms14. While research is underway to develop techniques to prevent trans-
mission of mtDNAmutations by transplanting nuclear DNA between zygotes15 or oocytes16, the development of
cellular therapies represents an important step towards treatment of degenerative diseases linked to mtDNA
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mutations. Given that pathology frequently develops in childhood,
the prospect of a lifetime on immunosuppressant drugs makes the
development of isogenic therapies for mtDNA disease a particularly
pressing goal.
Mitochondrial DNA is transmitted by maternal inheritance17, and
oocytes contain orders of magnitude more mtDNA copies than so-
matic cells18,19. Fusion of a whole somatic cell with an oocyte cyto-
plasm offers the theoretical possibility of developing NT-derived ES
cells in which mutated mtDNA is massively diluted by the mtDNA
present in the oocyte. However, the extent to which somatic cell
mtDNA persists in NT embryos appears to vary widely between
species and between different studies19. For example studies in sheep,
including Dolly, indicate that somatic cell mtDNA does not persist
following NT20, which raised the possibility that somatic cell mito-
chondria may be targeted for destruction by a mechanism analogous
to that responsible for elimination of sperm mitochondria following
fertilisation21. Since then, a number of studies have reported very low
levels of donor cell-derived mtDNA following NT in sheep19. By
contrast, studies in bovine NT embryos and offspring indicate that
somatic cell mtDNA persists to widely varying degrees19. The fate of
donor cell mtDNA in human oocytes is unknown. This question is
fundamental to the potential of NT in the development of isogenic
cell therapies for mtDNA disease.
To address this, we analysed mtDNA in NT-derived human
embryos. We found that the mitochondrial biomass of fibroblasts
is influenced by themethod used to induce arrest inGo/G1. However,
following NT, fibroblast mtDNAwas undetectable in the majority of
embryos and accounted for,2% of mtDNA content in the remain-
der. Development to the 4-cell stage when using amnion-derived
fibroblasts as a nuclear donor was comparable to activated control
embryos. However, consistent with the findings of others8,22, we
found that the efficiency of development beyond the 8-cell stage is
low. Thus, our data indicate that, with the use of optimised tech-
niques for NT as recently published9, isogenic cell therapies for
mtDNA disease could be feasible.
Results
Donor cell synchronisation and mitochondrial biomass.We used
adult skin fibroblasts or amnion-derived fibroblasts (Fig. 1a) from
donors who consented specifically to the use of their cells for NT
experiments. While skin fibroblasts have obvious advantages of
providing an easily accessible source of donor cells, amnion-
derived cells have been found to express some stem cell markers23
and are more amenable to reprogramming during iPSC derivation24,
and following NT in other species25. In relation to their therapeutic
potential, it would in principle be possible to store amnion of babies
born to women who carry mtDNA mutations.
Cell cycle arrest of somatic cells in G0/G1 is normally induced by a
prolonged period of confluency and/or serum deprivation before
they are used for NT26,27. FACS analysis indicates that both
approaches are effective in enriching for G0/G1 cells (Fig. 1b,
Supplementary Fig. S1). However, MitoTracker staining indicated
that cells maintained at confluency for 4 days had an increased
mitochondrial biomass compared with those cultured in serum-
deprived medium (Fig. 1c). We therefore used serum deprivation
with the aim of minimising somatic cell mtDNA content in NT
embryos.
Source of human oocytes. Human oocytes that fail to undergo
fertilisation in vitro, although abundant in supply, do not undergo
efficient activation and onward development following NT28. We
therefore used freshly harvested oocytes donated specifically for
this research. The majority of oocytes (n 5 239) were obtained
from women (n 5 26) undergoing IVF treatment who donated up
to half of their oocytes, in return for a contribution from research
funds towards the cost of their treatment29. A small number of
oocytes (n 5 26) were also donated by women (n 5 9) who had
oocytes harvested to reduce the risk of multiple pregnancy following
ovarian stimulation and intra-uterine insemination. From a total of
265 oocytes donated for the experiments described here, 224 (85%)
were arrested at meiosis II (MII), and were therefore considered
suitable for use in NT.
Modification of NT procedures for human oocytes. Our starting
point was to replicate the technical procedures used to produce NT-
derived rhesus monkey ES cell lines30. Freshly harvested human
oocytes were stripped of their cumulus cells and the spindle of
those found to be arrested at MII (Fig. 2a) were visualised by
polarised light birefringence (Fig. 2b and c) as previously
described30. However, we found that a number of modifications
were required to adapt NT procedures to human oocytes. Notably
laser-assisted thinning of the zona pellucida was required to reduce
the risk of oocyte lysis during enucleation. Furthermore, in initial
experiments, we found that the electrical pulses (2 3 130 V) used to
induce fusion in monkey NT30 resulted in poor rates of fusion with
human oocytes. We therefore used inactivated Sendai virus extract,
which includes fusogenic proteins of the viral envelope (HVJ-E,
Hemagglutinating Virus of Japan – Envelope; Fig. 2d). While HVJ-
E was highly effective in promoting successful fusion and oocyte
survival, our preliminary experiments indicated that the potential
for onward development was poor. Consistent with a recent
report9, we found that development was improved by electropo-
ration; the proportion of embryos arresting before the 8-cell stage
was reduced by applying two electrical pulses (2 3 70 V) following
HVJ-E-mediated fusion.
We next used these modified enucleation and fusion procedures
(Fig. 2e) in a series of experiments to compare the efficiency of NT
using adult skin and amnion-derived fibroblasts. The proportion of
oocytes surviving enucleation and fusion were 87.5% for adult skin
fibroblasts and 76.5% for amnion-derived fibroblasts (Fig. 2f).
To test the efficacy of the chemical activation procedures used to
trigger the onset of embryonic development followingNT inmonkey
oocytes30, we performed a series of experiments in which intact
oocytes were treated with ionomycin and 6-DMAP (6-
Dimethylaminopurine). As 6-DMAP inhibits formation of the sec-
ond polar body in intact mammalian oocytes31, activation gives rise
to diploid parthenotes containing two sets of maternal chromo-
somes. Activation was confirmed by the presence of pronuclei at
16–18 hours after exposure to ionomycin (Fig. 2g). By these criteria,
activation was observed in 90.9% of parthenotes and in 91.4% and
80.8% of NT embryos that survived enucleation and fusion with
adult skin and amnion fibroblasts respectively (not significant;
Fig. 2f). These data indicate that chemical activation with ionomycin
and 6-DMAP is effective in triggering exit from meiosis in human
oocytes, and that this is not adversely affected by replacement of the
maternal genome with that of a fibroblast.
In initial experiments we observed 2–3 pronuclei (Fig. 2g) in a
small proportion of NT embryos (9.4% and 14.3% respectively for
skin and amnion fibroblasts). This was sometimes, but not always,
associated with resorbtion of the first polar body.We thereforemodi-
fied the enucleation procedure to include removal of the polar body
as well as the spindle (Fig. 2e). In addition, multiple small nuclei
(Fig. 2g) were observed in a proportion (12.5%) of skin-derived
NT embryos, and in 6.7% of parthenotes. This is likely due to chro-
mosome scattering before exit from M-phase, which has been prev-
iously described following NT32.
To evaluate the effect of NT on embryonic development, we com-
pared the proportions of activated oocytes reaching key devel-
opmental milestones (Fig. 3a). Recent evidence from studies in
human embryos indicates that a first wave of embryonic transcrip-
tion can be detected at the 2–4 cell stage, and a further major wave
occurs at the 6–10 stage33. Embryos incubated with the transcription
www.nature.com/scientificreports
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Figure 1 | Cell cycle stage and mitochondrial biomass of fibroblasts used for NT. (a) Brightfield images of human adult skin and amnion-derived
fibroblasts in culture. Scale bar5 20 mm. (b) Flow cytometry traces showing enrichment for cells in G0/G1 in cell lines derived from adult skin or amnion.
The top panel represents cells maintained at confluency for 4 days. The bottom panel represents cells cultured in 0.5% serum for 3–5 days. Each trace is
representative of 3 independent experiments. Refer to Supplementary Figure S1 for an example flow cytometry trace for a population of proliferating
amnion fibroblasts. (c) Skin fibroblasts stained with DAPI and MitoTracker Red. Cells maintained at confluency for 4 days (top panel) show increased
mitochondrial biomass compared with those grown in 0.5% serum for 3–5 days (bottom panel). Scale bar 5 10 mm.
www.nature.com/scientificreports
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inhibitor a-amanitin from the 1-cell stage can develop to the 4-cell
stage34 or, occasionally, to the 4–8 cell stage when lower concentra-
tions are used22. Whereas those incubated in a-amanitin from 4-cell
stage either remain arrested with 4 cells, or progress to the 8-cell stage
and develop no further34. These data imply that the oocyte stockpile
of transcripts is sufficient to direct the first two rounds of cell divi-
sion, and is consistent with the second wave of transcription being
essential for development beyond the 8-cell stage.
To determine the effect of NT on the maternally-directed early
cleavage divisions, we compared the proportion of oocytes arresting
with# 4 cells following activation alone, or following NT using skin
or amnion fibroblasts. We found that the majority (62.5%) of skin
Figure 2 | Enucleation, fusion and activation of human oocytes. (a) Brightfield image of a human oocyte arrested at MII. Arrow indicates the first polar
body (PB). (b) The MII spindle of a human oocyte visualized by polarized light birefringence. Inset shows enlarged MII spindle. (c) Human oocyte
enucleated by aspirating a karyoplast containing the MII spindle into a beveled glass pipette using polarized light birefringence. Inset shows enlarged
image of the karyoplast containing the MII spindle. (d) Brightfield image of an enucleated human oocyte showing the donor fibroblast bathed in HVJ-E
solution positioned under the zona pellucida. Inset shows enlarged image of a fibroblast positioned for fusion. Scale bar5 100 mm. (e) Schematic drawing
of the NT procedure. The specific modifications of monkey NT procedures for human oocytes are highlighted in green boxes. (f) Table showing the
proportions of human oocytes undergoing successful enucleation, fusion and activation using themodified NT procedures for skin (n5 40) and amnion
(n5 34) fibroblasts. Unmanipulated parthenotes (n5 33), activated using ionomycin and 6-DMAP, were included as controls. (g) Images show example
cohorts of human parthenotes and NT embryos at 16–18 hr after exposure to ionomycin and 6-DMAP. Scale bar 5 100 mm.
www.nature.com/scientificreports
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fibroblast-derived NT embryos arrested with # 4 cells compared
with only 23.8% of those derived from amnion fibroblasts (P ,
0.01; Fig. 3b and 3c). The frequency of arrest at the 4-cell stage did
not differ between amnion-derived embryos and control parthenotes
(Fig. 3c), indicating that the NT procedure per se does not prevent
completion of the maternally-directed early cleavage divisions. The
high incidence of arrest in skin fibroblast-derived embryos may
reflect a response to chromosome segregation errors, which are pre-
valent in NT embryos32,35, or to DNA damage, which may be
increased in adult skin fibroblasts compared with amnion-derived
fibroblasts.
Of the NT embryos that progressed beyond the 4-cell stage, the
majority arrested during the next round of cell division with# 8 cells
(Fig. 3c). Nonetheless, compaction of embryonic cells, which marks
Figure 3 | Development of human parthenotes and NT embryos. (a) Schematic drawing showing development of chemically activated human embryos
from the pronucleate to the blastocyst stage. Development to the 4–8 cell stage is driven by the oocyte stockpile of maternal transcripts whereas
development to later stages requires transcription from the embryonic genome. (b) Images show examples of embryos on days 2–4 following activation of
unmanipulated oocytes (parthenotes), and NT embryos derived from either skin or amnion fibroblasts. Scale bar 5 100 mm. (c) Proportion of
parthenotes and NT embryos developing to each developmental stage during 6 days of culture following activation. (d) Images showing examples of
morulae and blastocysts derived from parthenotes and NT embryos as indicated. Scale bar 5 50 mm.
www.nature.com/scientificreports
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the first step in their allocation to the ICM and trophectoderm
lineages36, was observed in 6/32 (18.75%) of skin fibroblast-derived
embryos (Fig. 3c and 3d), but they did not develop further.
Interestingly, all of these were obtained from the same egg donor
and compaction occurred when the embryo contained relatively few
cells. Blastocyst formation was observed in 1/21 (4.7%) of the
amnion-derived NT embryos, compared with 7/30 (23.3%) of
parthenotes (Fig. 3e). While the amnion-derived blastocyst had a
discernible ICM, the trophectoderm appeared to contain few cells
(Fig. 3e). This is consistent with reports of impaired trophoblast
formation in mouse NT embryos37. Explantation of the NT-derived
ICM in conditions found to support successful derivation of human
ES cell lines38, did not result in the formation of a viable ES colony.
Donor cell mtDNA persistence in NT embryos. In the context of
mtDNA disease, the therapeutic potential of SCNT depends not only
on maximising blastocyst formation, but also on minimising
persistence of donor cell mtDNA. According to our current
understanding mtDNA does not replicate during the early stages
of embryonic development39, however, earlier replication has been
reported in some species following NT19. We therefore measured the
fibroblast mtDNA content in NT embryos (n 5 23) containing$ 4
cells obtained from 7 oocyte donors using amnion (n 5 14) and skin
(n 5 9) fibroblasts as donor cells.
ThemtDNA genotypes were determined by sequencing the highly
variable D-loop from donor fibroblasts and from ovarian follicle cells
obtained from the oocyte donors (Fig. 4a). Based on single nucleotide
polymorphic variants (Fig. 4b), we determined the levels of fibroblast
mtDNA contained in SCNT embryos by last hot cycle PCR restric-
tion fragment length polymorphism (RFLP). Donor cell mtDNAwas
below the limit of detection (,0.5%) in 60% of NT embryos (Fig. 4c
and 4d) and the maximum level was 0.2% (Fig. 4d). Persistence of
fibroblast mtDNA was similar between skin and amnion fibroblasts
(Fig. 4d).
To gain insight into whether the non-detectable levels observed in
the majority of embryos was due to elimination or dilution of donor
cell mtDNA, we measured mtDNA copy number in enucleated
oocytes, single skin fibroblasts, and single amnion fibroblasts
(Fig. 4e). Consistent with previous reports18, enucleated oocyte
mtDNA copy number varied by an order of magnitude. Skin and
amnion fibroblasts had similar mtDNA copy numbers (1,750 6
1,071 and 1,517 6 870 respectively). Assuming that the donor cell
mtDNA is neither preferentially replicated nor eliminated, we calcu-
lated the expected level of donor cell mtDNA based on all possible
combinations of donor cells and enucleated oocytes (n 5 144;
Fig. 4f). We found that 80% of values were below the limit of detec-
tion (,0.5%). This suggests that the non-detectable levels in 60% of
NT embryos (Fig. 4d) represent dilution rather than elimination of
donor cell mtDNA. Moreover, the range of values fitted closely with
the observed levels of donor cell mtDNA inNT embryos (Fig. 4d and
4f). Together, these data indicate that the donor cell mtDNA
accounts for a very low proportion of the total mtDNA in NT
embryos, and suggest that it is neither eliminated nor preferentially
replicated following NT.
While the low levels of fibroblast mtDNA present during early
development of NT embryos are encouraging, we cannot rule out
the possibility of preferential replication at later developmental
stages. Because of the limited development of NT embryos to later
stages, it was not possible to test this directly. However, low levels of
heteroplasmy have been reported in ES cells from embryos generated
by chemical activation following transplantation of MII spindles
between oocytes16,40. We therefore compared the mtDNA copy num-
bers of MII spindle-containing karyoplasts and fibroblasts (Fig. 5a).
The mtDNA copy number of karyoplasts (n 5 21) was highly vari-
able (Fig. 5a), ranging from 484 to 95,242, and generally higher than
that of fibroblasts (Fig. 5a). Consistent with this, we found that the
levels of heteroplasmy in embryos created following reciprocal trans-
fer of MII spindles between oocytes from different donors (Fig. 5b)
exceeded those of fibroblast-derived NT embryos (Fig. 4c, 4d, and
5e). In contrast to NT embryos, in which donor cell mtDNA was
below the limits of detection (0.5%) in 60% of embryos (Fig. 3d), we
found that karyoplast-associated mtDNA was below the limits of
detection in only 1/10 embryos derived from MII spindle transfer
oocytes (n 5 14; Fig. 5e). The levels measured in the remaining 9/10
embryos varied from 1–3% (Fig. 5e). These data together with the
finding that ES cells derived following MII spindle transfer contain
very low levels of heteroplasmy16,40 argue in favour of the therapeutic
potential of NT for mtDNA disease.
Discussion
Data presented here suggest that fibroblast mtDNA is neither elimi-
nated nor preferentially replicated following NT in human oocytes,
but is below the limit of detection in the majority of NT embryos,
most likely due to dilution by the high mtDNA copy numbers pre-
sent in oocytes. Our results, along with more recent technical
advances in human NT9, provide proof of principle for the use of
NT to develop isogenic ES cell-based therapies for the treatment of
degenerative disease associated with mtDNA mutations.
Furthermore, we demonstrated that the problem of obtaining human
oocytes can be overcome by donation through an ‘‘egg-sharing’’
scheme, which has a high level of acceptance among women under-
going IVF treatment29,41.
Our findings reveal new insights into the importance of donor cell
type and method of preparation for realising the therapeutic potential
of NT for mtDNA disease. First, we find that mitochondrial biomass
is increased in cells maintained at confluency, which is a commonly
used approach to induce cell cycle arrest in G1/G0 in preparation for
NT26,27. Thus, the level of donor cell mtDNA in NT-derived ES cell
lines is likely to be reduced by using serum deprivation rather than
confluency to induce arrest of donor cells in G1/G0. While serum
deprivation has been reported to induce donor cell apoptosis42,43,
serum deprived donor cells were used to generate human NT-derived
ES cells in the recent report from Tachibana et al9. Second, we find
that the use of adult skin-derived fibroblasts has a detrimental effect
on development to the 4-cell stage, whereas the use of amnion-
derived fibroblasts does not. This indicates that the maternally-direc-
ted phase of human embryonic development is not adversely affected
by the NT procedures per se, but that predisposing factors in fibro-
blasts from adult skin induce arrest during the early embryonic cell
divisions. This may be linked to chromosome segregation errors as
multiple small nuclei, which are indicative of chromosome scattering,
were observed in activated oocytes following transplantation of skin
but not amnion fibroblasts. The recent derivation of ES cell lines from
NT embryos9 was achieved using foetal dermal fibroblasts which, in
common with amniotic fibroblasts, may be more amenable to repro-
gramming and less prone to chromosome segregation errors. The
therapeutic potential of amnion-derived cells could be realised by
storing amnion from babies born to affected women.
Our findings indicate that fibroblast mtDNA persists at a very low
level due to dilution by the oocyte vast stock of mtDNA. While we
cannot rule out the possibilities that donor cell mtDNA content
might be affected by embryo viability, or that amplification of donor
cell derived mtDNA might occur at later stages, the latter seems
unlikely for a number of reasons. First, a number of ES cell lines
generated following MII spindle transfer in human oocytes show very
low levels of heteroplasmy16,40, and our data indicate that the levels of
heteroplasmy are lower following NT using either skin or amnion
fibroblasts compared with MII spindle transfer. Furthermore, so-
matic cell mtDNA was not detected in two triploid ES cell lines
generated from combined maternal and somatic cell genomes8.
The question of whether human NT can, in principle, be used to
develop cell-based therapies for degenerative disease associated with
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 4 : 3844 | DOI: 10.1038/srep03844 6
mtDNAmutations, has not previously been addressed. Together, our
data indicate that NT-derived ES cell lines are likely to carry very low
levels of mtDNA mutation and are therefore likely to be suitable for
therapeutic use. This approach would provide a means of repro-
gramming somatic cells to treat degenerative disease caused by
mtDNAmutations, with a greatly reduced risk of mtDNAmutations
persisting in the cells used for transplantation. Help for affected
families may also be possible through the development of assisted
reproductive techniques involving the transfer of parental chromo-
somes between fertilised15 or unfertilised16 eggs, to prevent transmis-
sion of mtDNA mutations from mother to child.
Methods
Licensing and approvals. The study was approved by the Local Research Ethics
Committee and was licensed by the UK Human Fertilisation and Embryology
Authority.
Figure 4 | Persistence of fibroblast mtDNA in NT embryos. (a) Sequence electropherogram of the mtDNA non-coding control region highlighting the
presence of a polymorphism (m.497 C.T) in amnion-derived fibroblast cells. This polymorphism was not detected in oocyte donor mtDNA obtained
from granulosa cells aspirated from ovarian follicles during the oocyte retrieval procedure. (b) Schematic illustrating restriction fragment length
polymorphism (RFLP) designed using the m.497C.T sequence variant. In the presence of the m.497C.T variant, digestion with the AciI enzyme
generates 2 fragments (441 115 bp). In the absence of the polymorphism 3 fragments (27, 441 88 bp) are created. (c) Radiolabeled restriction fragments
were separated by 12% non-denaturing polyacrylamide gel electrophoresis. E1–E7, NT embryos; OD, ovarian granulosa cells from the oocyte donor; F,
amnion fibroblasts; and U, uncut labelled PCR product. The percentage level of fibroblast mtDNA detected in each embryo is indicated (E1–E7). In this
example, the fibroblast mtDNA content was below the limit of detection (,0.5%) in 4/7 embryos. (d) Graph showing the level of fibroblast mtDNA as a
percentage of the entiremtDNA content ofNT embryos derived using skin (n5 9) or amnion (n5 14) fibroblasts. FibroblastmtDNAwas below the limit
of detection (,0.5%) in 6/9 skin fibroblast-derived NT embryos and in 6/14 amnion-derived NT embryos. (e) Table shows mtDNA copy number
measured in individual enucleated oocytes (n5 8) and in single skin (n5 9) amnion (n5 9) fibroblasts. (f) Graph shows hypothetical levels of fibroblast
mtDNA inNT embryos based on all possible combinations of enucleated oocytes and skin (n5 72) or amnion (n5 72) fibroblasts in whichmtDNA copy
number was measured.
www.nature.com/scientificreports
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Fibroblast culture and preparation for NT. Skin and amniotic fibroblast cell lines
were established from tissue obtained with consent from women undergoing
caesarean section. Tissue was chopped, treated with collagenase and cultured in
DMEM 1 10% FBS (Life Technologies). Cells were split using TrypLE Select (Life
Technologies) and frozen in 10%DMSO at passages 1–4. To induce arrest inG1/G0 by
serum deprivation, cells were thawed and cultured for two days in DMEM 1 10%
FBS, followed by 3–5 days of serum starvation in 0.5% FBS. Cells arrested in G0/G1 by
growing to confluency were cultured for 3–5 days and left for 4 days at confluency. For
both treatments cells were trypsinised and washed in G-MOPS medium (Vitrolife)
immediately before nuclear transfer.
DNA content analysis of fibroblasts. Following serum starvation for four days, or
culture to confluency, cells were dissociated with TrypLE (Invitrogen). Dissociated
cells were treated with nuclear extraction buffer (Partec), vortexed, and suspended in
extraction buffer (Partec) for 15minutes at room temperature. DNAwas stained with
DAPI (Partec) for 30 minutes and donor cell DNA content was determined with a
FACSCanto flow cytometer and Diva software (BD Biosciences).
Mitochondrial staining.Cells were incubated in culturemedium containing 100 nM
of MitoTracker Red (Life Technologies) for 30 minutes at 37uC. For brightfield
images, fibroblasts were imaged using a Nikon Eclipse TE2000-U inverted
microscope, a 20x/0.40 NA Plan Fluor objective and a cooled charge-coupled device
(CCD) camera (Oosight, CRi). For immunofluorescence, fibroblasts were imaged
using a Nikon Eclipse TE2000-U inverted microscope, a 10x/0.30 NA Plan Fluor
objective and a Photometrics CoolSnapHQ interline CCD camera (Roper Scientific).
Fibroblasts were illuminated using a Xenon bulb (Osram) and appropriate filter sets
(DAPI: Excitation 2Ax UV, Emission 2 Am, Dichroic UV-2A (Nikon). MitoTracker
Red: Excitation S580/20x, Emission S630/60m, Dichroic 86006 bs (Chroma Tech)).
The filter wheels and focus controllers (Prior Scientific) were driven by MetaMorph
(Universal Imaging) imaging software. Images were acquired using MetaMorph, and
processed using ImageJ software.
Oocyte preparation for nuclear transfer. Oocytes were donated by women
undergoing infertility treatment, either as part of an egg sharing programme or
following egg collection to prevent multiple pregnancy following ovarian stimulation
with exogenous gonadotrophins and intra-uterine insemination. Consenting women
shared if $6 oocytes were harvested. Women, from whom 5 or fewer oocytes were
collected, did not donate eggs but still received subsidised treatment29. Oocytes were
collected by ultrasound-guided follicle aspiration. The surrounding cumulus cells
were removed using hyaluronidase (HyAse, Vitrolife). MII oocytes were identified by
Figure 5 | mtDNA content of embryos derived following reciprocal transfer ofMII spindles between oocytes. (a) Box plot showsmtDNA copy number
in skin (n 5 9) and amnion (n 5 9) fibroblasts, and in MII spindle karyoplasts (n 5 21). (b) Schematic drawing showing reciprocal transfer of MII
spindles between oocytes. (c) Sequence electropherogram of the mtDNA non-coding control region highlighting the presence of a polymorphism
(m.16239C.T) in granulosa cells obtained from one of two oocyte donors (OD1 and OD2). (d) Schematic illustrating RFLP designed using the
m.16239C.T sequence variant. In the presence of the m.16239C.T variant, digestion with theMseI enzyme generates 3 fragments (32, 59 1 80 bp). In
the absence of the polymorphism 2 fragments (32 1 139 bp) are created. (e) Radiolabeled restriction fragments were separated by 12% non-denaturing
polyacrylamide gel electrophoresis. mtDNA was amplified from spindle transfer embryos and ovarian granulosa cells from two oocyte donors. Embryos
E1–E5 were generated by artificial activation of enucleated oocytes fromOD1 fused with spindle karyoplasts fromOD2. Embryos E6–E10 were generated
by artificial activation of enucleated oocytes from OD2 fused with karyoplasts from OD1. U, uncut labelled PCR product.
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the presence of the first polar body. Oocytes were incubated in G1 Plus medium
(Vitrolife) at 37uC and 7% CO2 until nuclear transfer.
Nuclear transfer. Micromanipulations were carried out on a Nikon TE-2000U,
equipped with Oosight birefringence imaging system (CRi), Integra Ti
micromanipulators and SAS air microinjectors (Research Instruments), Saturn
Active thermal laser (Research Instruments). The micromanipulation microscope,
dissection microscope, and incubators were contained within an enclosed
workstation in which the ambient conditions were maintained at 37uC and 7% CO244
(Vitrosafe Ltd). MII oocytes were transferred into the 5 ml droplets of G1 medium
(Vitrolife) containing 2.5 mg/ml of cytochalasin B (Sigma) under mineral oil
(Vitrolife), in glass-bottomed petri dishes (Willco). For enucleation, the spindle was
visualised by polarised light birefringence (Oosight, CRI). Oocytes were positioned on
a holding pipette with the spindle at the 4 o’clock position, where the zona pellucida
was thinned at a point adjacent to the spindle using a Saturn Active laser (Research
Instruments). A bevelled and spiked glass enucleation pipette with inner diameter of
20 mm was pushed through the thinned zona pellucida and the first polar body was
removed before the spindle was aspirated into the pipette. The pipette was then slowly
withdrawn, resulting in the ‘‘budding off’’ of a spindle karyoplast without breaking
the oocyte membrane. A suspension of prepared fibroblasts was placed in a small
droplet of culture medium supplemented with 0.5%HSA. In selecting cells for fusion,
we avoided abnormally small or large cells, or those showing signs of membrane
blebbing. Individual cells were briefly placed in a suspension of HVJ-E, GenomONE-
CF Ex (Cosmo Bio, Japan), and were aspirated into the pipette with one to two cell
volumes of HVJ-E suspension. The oocyte was positioned on the holding pipette with
the polar body at the 9 o’clock position. The zona pellucidawas thinned with the laser
at the 3 o’clock position and the pipette containing the fibroblast cell was pushed
through the remaining zona pellucida. The cell and HVJ-E solution were gently
expelled and the pipette withdrawn. Oocyte-somatic cell couplets were then
incubated for 1–2 hours prior to activation.
Embryos were imaged using either a Nikon SMZ-1000 stereo microscope on 83
magnification with a Nikon Digital Sight camera, or a Nikon Eclipse TE2000-U
inverted microscope, a 40x/0.60 NA PLAN APO objective and a cooled CCD camera
(Oosight, CRi).
MII spindle transfer. Enucleation was carried out as described and karyoplasts
containing spindles were fused with the enucleated oocytes using HVJ-E as described
above.
Activation and culture. NT oocytes were checked for membrane fusion prior to
activation and were transferred to 50550 G1: Fusion medium (0.25 M D-Sorbitol,
100 mM CaOAc, 500 mM MgOAc), and then straight fusion medium. One to three
NT oocytes were transferred between the electrodes of a BTX microslide chamber
filled with 25 ml of fusion medium. Two 70 V 50 ms electrical pulses were generated
by a BTX 830 electrofusion generator (BTX), fused couplets were then transferred to
50550 G1: Fusion medium and then into G1 culture medium.
Chemical activation was a four-step procedure. NT oocytes were first placed in a
solution of G1 with 1 mg/ml HSA, 5 mM ionomycin and 1 mM 6-dimethylamino-
purine (6-DMAP) for fiveminutes, thenG1with 30 mg/mlHSA, 1 mM6-DMAP for
5 mins, followed by G1 with 10 mg/ml HSA and 1 mM 6-DMAP for 5 hours.
Embryos were then carefully washed in G1 with 10 mg/ml HSA and cultured in G1
medium until day 3, when they were transferred to G2 culture medium (Vitrolife)
supplemented with 10 mg/ml HSA. Arrested embryos were individually transferred
to PBS in a PCR tube and stored at 220uC for mtDNA analysis.
mtDNA Sequencing. Themitochondrial genotypes of fibroblasts and granulosa cells
isolated from the ovarian follicular fluid of oocyte donors were identified by
sequencing the highly variable D-loop. DNA extraction was performed using the
QIAampH DNA Micro kit (Qiagen, Crawley, UK) as per the manufacturer’s
instructions. Isolated DNA (1 ml) was amplified in 25 ml reaction volumes using
overlapping M13-tailed primers targeted to the mtDNA D-loop (primer sets D1, D2,
D3 and D4), as described previously45. PCR product clean-up was carried out with
ExoSAP-IT (GE Healthcare, Buckinghamshire, UK). Samples were then sequenced
using BigDye Terminator v3.1 Cycle Sequencing chemistry (Applied Biosystems) on
an ABI3100 Genetic Analyzer (Applied Biosystems). The resulting sequences were
compared to the revised Cambridge Reference Sequence for human mtDNA
(GenBank reference NC_012920.1) using SeqScape software (v2.6. Applied
Biosystems).
Measurement of fibroblast and spindle karyoplast mtDNA content in NT and ST
embryos. The levels of mtDNA carryover from somatic cells and spindle karyoplasts
in reconstituted embryos were determined by last hot cycle PCR/restriction fragment
length polymorphism (RFLP) analysis. Embryos were first lysed for 2 hours at 55uC in
15 ml of a standard lysis buffer (50 mMTris-HCl, pH 8.5, 1 mMEDTA, 0.5%Tween-
20 and 200 mg/ml proteinase K), then incubated at 95uC for 10 minutes to inactivate
the enzyme. Last hot cycle PCR/RFLP assays were designed to target specific
polymorphisms that differed between the recipient oocyte and donor fibroblasts or
spindle karyoplasts and that resulted in the creation or removal of a restriction
enzyme recognition site. The assays were performed as described previously46 with
1 ml embryo lysate and the modifications detailed in Table 1.
MtDNA carryover was calculated as a percentage of total mtDNA present in
reconstituted embryos.
Measurement ofmtDNAcopy number.Amniotic and adult skin fibroblasts arrested
in G0/G1 were selected using the same criteria as for NT and frozen individually in
PBS in PCR tubes. Enucleated oocytes and spindle karyoplasts were frozen
individually in PCR tubes. MtDNA copy number was determined by real-time PCR
using established TaqMan probe and PCR primers targeting theMT-ND1 gene of the
mitochondrial genome47. Reactions were composed of 1 ml lysate, 300 nM forward
and reverse primers, 100 nM fluorogenic probe, and 12.5 ml TaqMan Universal
MasterMix (Applied Biosystems). Samples were analysed in triplicate. Mitochondrial
DNA copy numbers for enucleated oocytes, spindle karyoplasts and fibroblasts were
calculated from a standard curve produced from triplicate 10-fold serial dilutions of
an MT-ND1 template (nucleotide positions: 3017–4057) of known copy number.
Statistical analysis. Data are means 6 s.d. Statistical analysis was performed using a
student’s t-test. P , 0.05 was considered significant.
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